Diabetes, obesity & metabolism · 2026
Effect of Metformin Treatment on Gonadotropin Levels in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of 51 Randomised Controlled Trials.
Систематический обзорСтатьяМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Krysiak Robert, Simental-Mendía Mario, Simental-Mendía Luis E
Аннотация
AIMS: This study aimed to explore the impact of metformin on gonadotropin levels in women with polycystic ovary syndrome (PCOS) based on a meta-analysis of randomised controlled trials (RCTs).
METHODS: The search process was performed in PubMed, Scopus, Web of Science, ClinicalTrials.gov and Google Scholar. RCTs were eligible for meta-analysis if they had a parallel or crossover design and reported gonadotropin levels before and after metformin treatment. A random-effects model and the generic inverse variance method were used for meta-analysis.
RESULTS: The meta-analysis of 51 RCTs, 48 of which included only and 2 included predominantly women with PCOS, showed that metformin treatment did not affect FSH (WMD: -0.22 IU/L, 95% CI: -0.54, 0.11, p = 0.19, I2 = 84%) or LH (WMD: 0.11 IU/L, 95% CI: -0.38, 0.60, p = 0.66, I2 = 75%), but it significantly increased the LH/FSH ratio (WMD: 0.24%, 95% CI: 0.06, 0.43, p = 0.01, I2 = 93%). Additionally, the effect size was sensitive to one study for FSH, LH and LH/FSH ratio following the sensitivity analysis.
CONCLUSION: Our meta-analysis, the largest one conducted to date, indicates that metformin does not significantly affect circulating gonadotropin levels in reproductive-age women with PCOS.
METHODS: The search process was performed in PubMed, Scopus, Web of Science, ClinicalTrials.gov and Google Scholar. RCTs were eligible for meta-analysis if they had a parallel or crossover design and reported gonadotropin levels before and after metformin treatment. A random-effects model and the generic inverse variance method were used for meta-analysis.
RESULTS: The meta-analysis of 51 RCTs, 48 of which included only and 2 included predominantly women with PCOS, showed that metformin treatment did not affect FSH (WMD: -0.22 IU/L, 95% CI: -0.54, 0.11, p = 0.19, I2 = 84%) or LH (WMD: 0.11 IU/L, 95% CI: -0.38, 0.60, p = 0.66, I2 = 75%), but it significantly increased the LH/FSH ratio (WMD: 0.24%, 95% CI: 0.06, 0.43, p = 0.01, I2 = 93%). Additionally, the effect size was sensitive to one study for FSH, LH and LH/FSH ratio following the sensitivity analysis.
CONCLUSION: Our meta-analysis, the largest one conducted to date, indicates that metformin does not significantly affect circulating gonadotropin levels in reproductive-age women with PCOS.